Related Experiment Video

Updated: Aug 25, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC

Wei Xiao1, Pankaj Ahluwalia1, Lan Wang1

  • 1Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

Cells
|October 14, 2022
PubMed

Insights

Tissue inhibitor of metalloproteinase-1 (TIMP-1) drives chemoresistance in non-small cell lung cancer (NSCLC) by altering cell metabolism. This involves mitochondrial changes mediated by STAT3 acetylation, impacting treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Chemoresistance is a major challenge in non-small cell lung cancer (NSCLC) treatment.
  • Altered cancer cell metabolism is a key mechanism underlying chemoresistance.

Purpose of the Study:

  • To investigate the role of aberrant metabolism in TIMP-1-mediated chemoresistance in NSCLC.
  • To elucidate the molecular mechanisms by which TIMP-1 influences cancer cell metabolism.

Main Methods:

  • Bioinformatics analysis to identify associations between TIMP-1 and energy metabolism.
  • Experimental validation of mitochondrial function, including lactate secretion, ROS levels, and GSH levels.
  • Investigation of the role of STAT3 acetylation and its interaction with CD44.
  • Correlation of CD44, STAT3, and TIMP-1 immunoexpression in patient samples.
  • Analysis of TCGA-LUAD dataset for gene expression signatures.

Main Results:

  • High TIMP-1 expression correlates with altered energy metabolism and chemoresistance.
  • TIMP-1 modulates mitochondrial metabolism via acetylation of mitochondrial STAT3, affecting its monomeric and dimeric forms.
  • Depolarized mitochondria, reduced lactate secretion, higher ROS, and reduced GSH levels were observed in TIMP-1 knockdown cells.
  • The CD44-STAT3 axis is crucial for TIMP-1's metabolic modulation.
  • A five-gene signature including TIMP-1 is associated with immunosuppressive cells and poorer overall survival in NSCLC.

Conclusions:

  • TIMP-1 promotes chemoresistance in NSCLC by reprogramming mitochondrial metabolism through STAT3 acetylation and the CD44-STAT3 axis.
  • Understanding these metabolic alterations offers potential therapeutic targets and prognostic markers for NSCLC.
Keywords:
CD44NSCLCSTAT3TIMP-1altered metabolismbioinformatic analysischemoresistance

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K